Type: Abstract

Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets

Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA).

An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM)

Racial and ethnic representation in large B-cell lymphoma trials and real-world databases.

Outcomes among Hispanic metastatic breast cancer patients treated with alpelisib and fulvestrant: Single institution retrospective study.

Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA)

REALM (OP-RW001): Comparing the Characteristics and Clinical Outcomes of Patients with Relapsed/Refractory Multiple Myeloma in the Real World to Patients Receiving Melflufen in the Horizon Study

MM-123: Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US

MA14.01 Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non–Small Cell Lung Cancer

Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy